56 related articles for article (PubMed ID: 8372547)
1. Arginase activity alterations in peripheral blood lymphocytes in the human chronic lymphocytic leukemia.
Konarska L; Widzyńska I; Zienkiewicz H; Sułek K
Acta Biochim Pol; 1993; 40(1):160-3. PubMed ID: 8372547
[No Abstract] [Full Text] [Related]
2. [NAD- and NADP-diaphorase activity in the peripheral blood lymphocytes of patients with the B-cell variant of chronic lympholeukemia].
Fed'ko AA; Guseva SA; Tishchenko LM; Poliachenko LIu
Vrach Delo; 1991 Mar; (3):47-9. PubMed ID: 2042348
[TBL] [Abstract][Full Text] [Related]
3. Purification of arginases from human-leukemic lymphocytes and granulocytes: study of their physicochemical and kinetic properties.
Reyero C; Dorner F
Eur J Biochem; 1975 Aug; 56(1):137-47. PubMed ID: 240702
[TBL] [Abstract][Full Text] [Related]
4. Glutamate dehydrogenase activity in lymphocytes of B-cell chronic lymphocytic leukaemia patients.
Pajic T; Cernelc P; Sesek Briski A; Lejko-Zupanc T; Malesic I
Clin Biochem; 2009 Nov; 42(16-17):1677-84. PubMed ID: 19683518
[TBL] [Abstract][Full Text] [Related]
5. The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.
Gamberale R; Fernández-Calotti P; Sánchez-Avalos J; Alberto MF; Geffner J; Giordano M
Haematologica; 2006 Apr; 91(4):574-6. PubMed ID: 16533725
[TBL] [Abstract][Full Text] [Related]
6. [Comparative characterization of altered activity of lysosomal cysteine proteinases in various leukocytic fractions inpatients with chronic lymphocytic leukemia].
Stroev EA; Boriskina MA
Vestn Ross Akad Med Nauk; 1996; (10):33-6. PubMed ID: 8998431
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
[TBL] [Abstract][Full Text] [Related]
8. Micronucleoli in lymphocytes of the peripheral blood of patients suffering from chronic lymphocytic leukemia (B type).
Smetana K; Subrtová H; Jirásková I; Rosa L
Sb Lek; 1995; 96(2):69-74. PubMed ID: 8718790
[TBL] [Abstract][Full Text] [Related]
9. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
10. NAD+ metabolism in lymphocytes of patients affected by B-cell chronic lymphocytic leukaemia.
Polzonetti V; Pucciarelli S; Signorello L; Vita A; Vincenzetti S; Natalini P
Int J Immunopathol Pharmacol; 2004; 17(3 Suppl):1-6. PubMed ID: 16857098
[TBL] [Abstract][Full Text] [Related]
11. ZAP70 in chronic lymphocytic leukaemia.
Amin S; Parker A; Mann J
Int J Biochem Cell Biol; 2008; 40(9):1654-8. PubMed ID: 17625948
[TBL] [Abstract][Full Text] [Related]
12. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Lin K; Glenn MA; Harris RJ; Duckworth AD; Dennett S; Cawley JC; Zuzel M; Slupsky JR
Cancer Res; 2006 Aug; 66(15):7801-9. PubMed ID: 16885384
[TBL] [Abstract][Full Text] [Related]
13. Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells.
Täger M; Kröning H; Thiel U; Ansorge S
Exp Hematol; 1997 Jul; 25(7):601-7. PubMed ID: 9216735
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia.
Ghia P; Ferreri AM; Caligaris-Cappio F
Crit Rev Oncol Hematol; 2007 Dec; 64(3):234-46. PubMed ID: 17544290
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Kelley TW; Alkan S; Srkalovic G; Hsi ED
Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
[TBL] [Abstract][Full Text] [Related]
16. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
17. [Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
Takeuchi M; Tada A; Soda R; Takahashi K
Rinsho Ketsueki; 1997 Sep; 38(9):792-4. PubMed ID: 9364873
[TBL] [Abstract][Full Text] [Related]
18. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt AR; Sherrington PD; Cawley JC
Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
Hematol Cell Ther; 1999 Jun; 41(3):127-36. PubMed ID: 10456443
[No Abstract] [Full Text] [Related]
20. Relation between the activity of poly(A)polymerase and the levels of protein synthesis in the lymphocytes of patients with chronic lymphocytic leukemia.
Gounaris A; Courtis N; Pangalis GA; Tsiapalis CM; Trangas T
Blut; 1988 Nov; 57(5):293-6. PubMed ID: 2848602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
